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Background. Stenting has become the first-line treatment of obstructive venous disease because of poor results of balloon
angioplasty. This preclinical study aimed to investigate the safety and efficacy profile of a novel compliant venous scaffold (CVS)
denominated Petalo CVS, specifically designed for venous diseases. Materials and Methods. Twelve healthy pigs weighing 90 kg
were used to test Petalo CVS. The devices were implanted into the internal jugular veins (IJVs) using a femoral vein percutaneous
approach. The safety profile including the success rate of device releasing, anchoring, and positioning was evaluated immediately.
Fracture, migration, primary patency, and endothelial response were assessed at 1, 2, 3, and 6 months after the study procedure.
Results. A total of 32 devices were successfully released in both IJVs. No procedure- or device-related complications were reported,
and all pigs successfully completed the different scheduled follow-up periods. The primary patency rate was 100%, and no fracture
or migration of the device into the brachiocephalic trunk was reported. Histological examination revealed only minimal lesions
with minimal or absent inflammatory reaction surrounding the incorporated metallic rods. Conclusions. This porcine model study
showed a promising safety and efficacy profile of Petalo CVS, a novel endovenous device based on specific concepts.
1. Introduction
Endovenous balloon angioplasty is used to treat occlusive
venous disease.This procedure has a satisfactory safety profile
but with low patency and clinical improvement rates. It
shows minimum interference of the core nature of venous
hemodynamics and related collapsibility. Due to the poor
results of balloon angioplasty, stenting is used with increas-
ing frequency in patients with venous chronic obstructive
disease. Endovenous stenting results in improved midterm
patency compared with balloon dilatation [1–4].
An ideal venous stent design should consider the com-
pliance of the venous system to the hydrostatic pressure,
continuously modified by the postural changes of the body.
The most recent endovenous stents are mainly derived from
arterial stent concepts, with a potentially high radial force
and resistance to compression; thus, they fall short of these
requirements.
In this porcine model study, the safety, efficacy, and
endothelial response of Petalo CVS, a novel nitinol device,
specifically based on venous properties, were evaluated.
2. Materials and Methods
Twelve healthy pigs were used to test Petalo CVS, a novel
specific scaffold based on venous properties. The study was
Hindawi
BioMed Research International
Volume 2018, Article ID 7312315, 8 pages
https://doi.org/10.1155/2018/7312315
2 BioMed Research International
(a) (b) (c)
Figure 1: Petalo CVS prototypes: scaffold shape evolutions. In the first prototype (a), the heads of the bridges (arrows) between the modules
are directed upwards; in the second prototype (b), the heads are directed downwards; and in the final prototype (c), the heads are in a “kissing”
position to minimize the risk of vein perforation and improve the collapsibility of the scaffold. Moreover, in the final prototype, the upper
extremities of the modules (∗) are oriented with an external configuration to reduce the contact area and minimize the risk of migration.
approved by the local ethics committee of University of
Milan and the Italian Ministry of Health (MoH). The study
was conducted following the guidelines of good laboratory
practices and received a grant from the National MoH.
The internal jugular vein (IJV) was used in this study
model because of its similarity in size and length to the human
IJV. Moreover, it can be easily approached by a femoral
vein percutaneous access and monitored using Doppler
ultrasound. It also offers a valuable stress site for migration
and fracture of the device due to the frequentmovements and
torsion of the neck, and likely compression by neck muscles.
Finally, the IJV can be easily retrieved for macroscopic and
histological examinations at the end of the study.
2.1. Experimental Venous Device. The prototypes were fabri-
cated by Admedes Schuessler GMBH (Pforzheim, Germany)
using a cut-laser nitinol technology. Petalo CVS has two
Italian patents and a European patent (PL2914214 (T3), 2017-
07-31).
Petalo CVS has a tubular concave shape with 4 support
modules joined by transverse bridges (Figure 1).
Themodules are oriented longitudinally and extend along
the entire length of the device’s body. The concavity of
the four modules is oriented toward the vein wall. The
support modules are internally empty, without bridges or
other internal elements, tominimize themetal structure. Two
transversal bridges join the support modules in the central
part of the body, leaving the extremity of the modules free
and open. The transversal bridges have a gull-wing shape.
The joined bridges enhance the conformability of the device
and reduce the radial force.The concave shape of the support
moduleswas studied to reduce the contact between the device
and vein wall, with the aim of decreasing inflammatory
response. Three prototypes with the same shape and length
were tested, and the one with higher radial force was chosen.
The prototype had proximal (nearest to the heart) and distal
diameters of 12mm and 14mm, respectively. Two devices
with different lengths (38mm and 48mm) but the same
diameters were used for the study. The longer device had an
increased radial force than the shorter one. The study device
was designed to provide a scaffold for the venous wall to treat
endoluminal defects, stenosis, and extrinsic compression
of intracerebral venous sinus and peripheral straight veins.
Petalo CVS enables the veins to physiologically adapt its
cross-sectional area to the flow and hydrostatic changes by
collapsing when pressure and/or flow rate decreases. This
avoids the persistent dilatation of the vein wall observed with
available venous stents and finally contributes tomaintain the
physiological compliance of the venous wall.
2.2. Animal Model and Study Protocol. Twelve healthy pigs
weighing 90 kg were used in the experimental study.
The experimental study was performed in two phases.
Phase 1 was defined as the procedure of device delivery,
and phase 2 was the procedure of control and harvesting
of the target veins. Phase 1 procedures were performed for
three consecutive days (four pigs per day). All endovas-
cular procedures were conducted under general anesthesia
using a standard protocol and monitoring of cardiac and
respiratory parameters. The percutaneous approach to the
venous system and catheter venography was similar to that
performed normally in humans and already described in a
previous paper [5]. In brief, access to the venous system was
achieved through a percutaneous antegrade approach of the
right common femoral vein under sonographic guidance to
avoid accidental arterial puncture. After placement of a 9 F
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sheath introducer (Boston Scientific, Natick, Massachusetts),
an intravenous bolus of 5,000U of heparin was adminis-
tered. The right IJV was first cannulated using a 0.035-inch
short-angle regular hydrophilic guide wire 260 cm in length
(Aquatrack; Cordis, Bridgewater, New Jersey) supported by a
BER II diagnostic catheter (4 F, 100 cm; Cordis). The BER II
catheter, a straight catheter with a short distal angulation of
the tip, was preferred to minimize possible interference with
any endoluminal defects of the IJVs. Selective venography
of the IJVs was performed by manual injection of a low-
viscosity contrast medium (Iomeron 150; Bracco Imaging,
Milano, Italy) in anterior-posterior projection. Subsequently,
at least one device was inserted in the proximal or medium
tract of the IJV or at the site of valve apparatus using a
standard pull-back stent delivery system (Video 1). A new
phlebography was performed to evaluate the position of the
device, the patency of the vein, and time of clearance of
contrast medium as parameters of flow characteristics. The
same procedure was performed for the left jugular vein. At
least two devices with different lengths were inserted for each
pig. At the end of the procedure, the inguinal introducer was
removed, and light manual compression of the access site was
performed.Theprocedurewas now considered complete, and
the pig was extubated and placed in the animal house. All
pigs received a daily oral dose of 100mg of acetylsalicylic
acid for 1 month. Every minor or major adverse event at
the access site, or related to the procedure or devices, was
accurately monitored in each pig. Monitoring was performed
in all awake pigs and during the postoperative period to avoid
adverse events and harm. Phase 2 procedures were performed
at different scheduled times: 1 month (4 pigs), 2 months
(2 pigs), 3 months (2 pigs), and six months (4 pigs) after
phase 1 procedures. All pigs underwent a new endovascular
procedure and an open surgery procurement of the target
veins using the same anesthetic and endovascular protocols of
phase 1 procedures described previously.The correct position
of the device (migration) using bone markers, integrity of
the scaffold (fracture), and patency of all segments of the
IJV including the scaffold were evaluated and documented,
together with the clearance of contrast medium (Video 2).
The IJVs were then isolated through a standard cutdown
technique to evaluate the elasticity and persistence of compli-
ance of the vein wall using two methods. Manual hydrostatic
dilatation of the vein was initially performed by low-pressure
injection of sterile solution through a direct puncture of
distal IJVs, simulating an increase of the flow volume and
pressure.The bedwas thenmoved in Trendelenburg and anti-
Trendelenburg positions to evaluate the changes of the cross-
sectional area of the veins. Finally, IJVs including the device
were removed to examine the macroscopic and microscopic
changes of the veinwall in response to the device.Histological
examination of the target vein samples was performed at two
blinded laboratories.
The surgical specimen included a vein portion of at least
2 cm in length proximally and distally to the device. For the
histological analyses, samples were fixed in formalin 10% for
24 h at 4∘C and subsequently rinsed in several changes of cold
70% ethanol.The tissues were dehydrated through an alcohol
series and then paraffin-embedded using a Shandon Citadel
2000Tissue Processor. After blocking out, 5 𝜇mthick sections
were cut, stained with haematoxylin and eosin (Bio Optica
SPA, Milano, Italy), and/or used for immunohistochemistry
with the Ab anti-von Willebrand Factor (vWF) (FVIII)
(Dako, Carpinteria, CA). In each slide, a negative control was
obtained carrying out the immunohistochemistry procedure
without the primary antibody. All the sections were acquired
with a light microscope (Eclipse TE200 InvertedMicroscope;
Nikon, Tokyo, Japan).Allmetallic rodswere removed to allow
histological processing. For the wall thickness evaluation, dif-
ferent sections were acquired and digitalised with an Aperio
ScanScope slide scanner and the thickness values of the
jugular walls were estimated by using the Aperio ImageScope
v11.1.2.760 software (Leica Biosystems, Nussloch, Germany).
For each tissue section, the total wall thickness was obtained
from at least 3 randomly selected areas within the slide. All
haematoxylin and eosin-stained jugular vein sections were
examined by the study pathologist for semiquantitative and
descriptive histopathology and for assessment of inflamma-
tory cells and infiltration of lymphoid tissue around the
empty area previously occupied bymetallic rods of the device.
The pigs were sacrificed at the end of the procedure under
deep general anesthesia with intravenous administration of
Tanax. All data related to positioning and follow-up of the
endovascular device, including the diagnostic procedures and
open surgery harvesting of the target vein, were recorded in
an electronic database and hard clinical report. All the study
procedures were video recorded. All the videos were stored
and classified based on the type and time of the procedure.
A brief summary of the most significant moments of each
procedure was created to make the final video. Images from
all surgical specimens were taken, and all specimens were
classified accordingly.
2.3. Endpoints. The study evaluated a composite of safety
and efficacy endpoints. The safety profile included successful
delivery and positioning, rate of migration and fracture of
the device, and rupture and bleeding of the target vein. Major
adverse events (MAE) were defined as death, severe cardiac
arrhythmia, and need for open surgery repair. The primary
efficacy endpoints were primary patency of the devices,
absence of thrombus of the target IJV, persistent elasticity, and
compliance of venous wall. The endothelial response to the
device was evaluated during histological examination of the
target veins.
3. Statistical Analysis
The anatomical characteristics of all pigs and intraoper-
ative and postoperative details were collected in a dedi-
cated spreadsheet (excel software). The collected data were
expressed as means ± standard deviation and percentages.
For stratified analysis, 𝜒2 test was used to compare different
outcomes, and the associated 𝑃 value < 0.05 was considered
significant. Device primary patency, freedom from inner
and outer IJV stent graft migration, and survival rates
were reported with Kaplan-Meier method using dedicated
software (Rstudio package, Version 0.99.902, © 2009–2016
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Table 1: Baseline characteristics and operative details of the study population, comparing the two different devices used for the study.
Stent 1 (14–12 × 38mm) Stent 2 (14–12 × 48mm) Significance (𝑃 value)
Devices, 𝑛 (%) 21 (65.6) 11 (34.4) NA
Right IJV devices, 𝑛 (%) 10 (31.2) 6 (18.8) 0.886∗
Left IJV devices, 𝑛 (%) 11 (34.49) 4 (12.5) 0.886∗
Anterior IJV devices, 𝑛 (%) 0 (0.0) 1 (3.2) NA
Middle IJV device implantation 14 (43.8) 8 (25.0) 0.991∗
Proximal IJV device implantation 7 (21.9) 3 (9.3) 0.991∗
Device implantation > 1
(i) RIJV 2 1 (in overlapping with stent 1) NA
(ii) LIJV 4
Death, 𝑛 (%) 0 (0.0) 0 (0.0) NA
Reinterventions, 𝑛 (%) 0 (0.0) 0 (0.0) NA
Stent graft fracture, 𝑛 (%) 0 (0.0) 0 (0.0) NA
Inner IJV stent graft migration, 𝑛 (%) 3 (9.3) 3 (9.3) 0.714∗
Major IJV stent graft migration, 𝑛 (%) 0 (0.0) 0 (0.0) NA
1-month patency, 𝑛 (%) 21/21 (100) 11/11 (100) 1.000∗
3-month patency, 𝑛 (%) 10/10 (100) 7/7 (100) 1.000∗
6-month patency, 𝑛 (%) 6/6 (100) 5/5 (100) 1.000∗
IJV: internal jugular vein; RIJV: right internal jugular vein; LIJV: left internal jugular vein; ∗𝑃 value determined using a Chi-square test. Pearson’s Chi-squared
test with Yates’ continuity correction.
RStudio, Inc., Boston, USA). Curves are displayed up to a
value of standard error <.10. A 95% confidence interval was
used for all variables of the underlying distribution.
4. Results
A total of 12 pigs were included in the study, and the proce-
dures were successfully completed in all pigs. Percutaneous
access to the venous system was achieved in 96% of cases
(23/24). A cutdown access was requested in one case. The
right common femoral vein was used in the majority of
cases (23/24).Thirty-two devices were implanted in both IJVs
(mean 2.67 ± 0.65): 21 devices, 14–12 × 38mm; and 11 devices,
14–12 × 48mm. In 7 IJVs (4 RIJV and 3 LIJV), two devices
were implanted: one in the proximal segment of IJV and the
other in medium portion. In the remaining 18 cases, a single
device was implanted (Table 1).
All the devices were placed successfully. The positioning
was precise, and no immediate migration occurred. In all
cases, the devices were able to control the leaflets of the valve.
No deaths orMAEwere documented, and all pigs reached the
scheduled phase 2 procedures (Figure 2).
No significant differences were found between the two
devices in terms of patency, reintervention, survival, and
inner JV migration rates.
In phase 2 procedures, no fractures or migration of the
scaffold in the brachiocephalic trunk or in the right atrium
were reported. In 6 of 32 devices (18.7%), a proximal migra-
tion confined to IJV segment was reported. The freedom
from inner IJV stent migration rate was 90.6% at 1 month,
83.4% at 3 months, and 78.5% at 6 months from intervention
(Figure 3).
Despite the discontinuation of antiplatelet therapy after
the first month, all veins and devices were patent (primary
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Figure 2: Kaplan-Meier curve demonstrating excellent survival.
patency of 100%) at the scheduled phase 2 procedures
(Figure 4).
During the standard cutdown of the neck, the isolation of
the entire target IJV allowed us to demonstrate the absence
of adventitial inflammatory response. The target veins were
easily detached from the surrounding tissues due to the
absence of fibrosis and adhesions (Figure 5).
No fractures or perforations of the target vein were docu-
mented. The target IJVs, including the scaffolds, maintained
the physiological compliance. In all target IJVs, the variation
of vein diameter by the means of partial collapse of the
vein wall into the free modules of the device in response to
flow volume and pressure changes and body position were
documented (Video 3). After the removal of the target IJVs
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Figure 3: Kaplan-Meier analysis of 6-month freedom from inner
IJV stent graft migration demonstrating a low rate of inner migra-
tion, confirming the excellent stability of the device.
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Figure 4: Kaplan-Meier analysis of primary patency. All devices
were patent at the scheduled follow-up times.
including the device, the vessel was opened longitudinally
and then evaluated (Figure 6).
The devices were incorporated with a light tissue in
the vein wall mainly at the extremities, without signs of
endoluminal thrombus. No fracture of the support modules
or the transversal bridges of the scaffold was documented.
The gross anatomy of the vein wall distally and proximally
to the device was normal. The portion of the vein between
the modules showed an intact endothelial layer and absence
of fibrosis. Histological examination revealed only minimal
lesions characterized by villous proliferation of the endothe-
lial surface and subendothelial fibrosis, with minimal or
absent inflammatory reaction surrounding the inglobated
metallic rods. Inflammatory response was indicated by the
presence of fibrocytes and, in some cases, by rare inflam-
matory cells typical of chronic processes (lymphocytes and
macrophages). Finally, the thickness of the wall and the tissue
Figure 5: Intraoperative view showing the Petalo CVS implanted in
left IJV (arrows). Note the absence of inflammatory reaction of the
adventitia and tissue surrounding the vein.
Figure 6: Six-month follow-up. Macroscopic view of the internal
surface of a small jugular vein containing Petalo CVS. The device
was incorporated in the vein wall mainly at the extremities (Region
2) by a light tissue. Neointimal hyperplasia was absent.Moreover, no
fracture of the supportmodules or transversal bridges of the scaffold
were documented. Presence of thrombus was not noted. Region 1:
control area; region 2: distal device area; and region 3: middle device
area.
covering the device in the distal region was comparable to
that of the sections obtained at 3 and 6 months after the
procedure (Figure 7).
5. Discussion
Obstructive venous diseases, such as hypoplasia, intralumi-
nal defects, and extrinsic compression, may have different
hemodynamic effects on the venous system depending on the
location, extent, severity, and lack of compensation through
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(A)
(a) Region 1: control area
(b) Region 2: distal device
(c) Region 3: middle device
Region 1 = control area
Region 2 = distal device
Region 3 = middle device
Figure 7: Morphological analyses of internal jugular veins implanted with Petalo CVS for 6 months. Six months after the implant, the swine
were sacrificed and IJV were collected for morphological analyses. In (A), gross luminal view of the stent-grafted IJV at 6 months is shown.
Representative histological images (hematoxylin-eosin stain) of control (a), distal (b), and middle (c) regions of the IJV are shown. ∗∗Empty
spaces before being occupied by metallic rods. ∗Inflammatory area.
collateral pathways [6–10]. Endovenous angioplasty with
stenting of iliac vein shows a good safety profile of >90%
in nonthrombotic limbs and >80% in thrombotic limbs [11–
16]. Venous sinus stenting to reduce intracranial pressure in
idiopathic intracranial hypertension results in a significant
improvement of neurological outcomes, including headache
and cognitive dysfunction [17, 18].
Stenosis due to endoluminal anomalies in the form
of malfunctioning valves, septa, or membranes was doc-
umented in the IJV tract close to the junction with the
subclavian vein and the outlet into the brachiocephalic vein
[6]. Recently, IJV stenosis has been treated using endovascu-
lar treatment (either PTA or stenting), with positive results
in terms of neurological outcomes and/or effects on the
quality of life [19–24]. Nevertheless, angioplasty of IJVs is
complicated by a high rate of early stenotic recurrence, with
incidence of restenosis between 30% and 50% of cases [23–
25]. Such high restenosis rates suggest that discussion of
inadequate treatment may be more appropriate rather than
restenosis or recurrence. Otherwise, stenting of IJVs showed
a good efficacy profile with no immediate increase of risk.
However, long-term results are not encouraging due to high
rate of restenosis [24, 25]. The current design of stents for the
venous system shows improved and continuous radial force
and resistance to compression. The increasing diameter of
vessel toward the heart requires an oversized stent diameter
to avoid migration. Permanent overdilatation determines
the peripheral slowdown of the flow and the loss of the
physiological compliance of the vein [6]. This new device
was designed with full consideration of the “collapsible”
nature of the vein, which is responsible for great variation
in venous capacity with little change in venous pressure.
A major change in volume with minimal pressure change
is largely due to the cross section of the venous lumen;
the elliptical contour at low transmural pressures becomes
circular at high transmural pressures [6]. The elliptical cross
section in a partially collapsed state has far more resistance
than the circular cross section; the vein is distended and
resistance falls, allowing an increase in blood flow with little
increase in the energy gradient. Little increase in pressure is
required to convert a low-volume elliptical tube into a high-
volume circular tube (e.g., increase of transmural pressure
from 0 to 15mmHg increases the volume of vein for more
than 250%).However,more pressure is required to stretch the
venous wall once the circular configuration has been reached
[6]. Hence, mechanically paradoxical venous system with
unique condition of “venous pressure and venous volume
may decrease as flow increases and may increase as flow
decreases or reverses” (cf. arterial system; pressure, volume,
and flow change in the same direction) can fulfill its role as
energy-efficient storage facility of blood [6].
Petalo CVS was developed considering the main charac-
teristics of the vein, that is, the delicate and elastic venous
wall and the capacity to adapt its cross-sectional area to flow
volume and pressure changes.
Petalo CVS promotes only minimal response of the vein
wall, with a primary patency of 100% in scheduled phase 2
procedures. The patency of the target veins was maintained
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without the need of any specific anticoagulant therapy. The
shape and configuration of this device avoid migration out-
side the target veins and fractures of the scaffold, despite the
light structure and reduced radial force. The reported minor
proximal migration rate of 20% confined to IJV segment was
probably a consequence of larger diameters of the vein wall at
the IJV bulb.
The restriction policy of the Italian Minister of Health
to prevent animal suffering did not allow us to perform a
comparative study with conventional stents. However, the
aim of this preclinical study was to evaluate the safety and
efficacy of this new venous scaffold in a healthy animalmodel,
without presumption of superiority to conventional stents.
Petalo CVS was implanted at the valve site of healthy
IJVs; thus, the efficacy of this device in cases of chronically
occluded and scarred veins was not documented. However,
the documented precise and stable positioning, control of
valve leaflet movement, and absence of fracture of the
scaffold, and, finally, the minimal inflammatory response of
the vein wall could encourage the use of Petalo CVS in the
treatment of venous obstructive diseases.
6. Conclusions
This study documented a favourable safety profile of Petalo
CVS, a novel endovenous device based on specific concepts.
The novel configuration of the scaffold and the respect of
the compliance of venous wall provided an excellent patency,
even without the use of anticoagulant drugs.
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Supplementary Materials
Video 1: procedure of device delivery into the left internal
jugular vein. After accessing the venous system through
a percutaneous antegrade approach of the right common
femoral vein, the left internal jugular vein was cannulated.
The selective venography of the internal jugular vein showed
a patent vein with a well visible valve apparatus (marked with
∨ on the screen). The device was implanted and released at
the site of the valve apparatus (marked with black points)
via a standard pull-back stent delivery system. The control
phlebography demonstrated the patency of the vein, while the
valve apparatus was not clearly visible. The postprocedural
echo-color Doppler demonstrated the patency of the vein
and the correct positioning of the device. Video 2: six-
month follow-up. The selective venography of the right
internal jugular vein demonstrated the correct positioning
of the device with no signs of fracture and the patency
of the vein with a normal contrast medium clearance. The
device was perfectly compliant with the vein wall; this is
the proof of the concept of the device, which allows the
maintenance of the collapsibility and the elasticity properties
of the vein wall. Video 3: 6-month follow-up. Intraoperative
view. The jugular vein has been dissected before retrieval for
histological analysis, and the device is clearly visible inside
the vein. Notably, the partial collapse of the vein wall into the
free modules of the device allows the adapting of its cross-
sectional area to volume changes. (Supplementary Materials)
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